succinobucol has been researched along with Hyperlipemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kourounakis, AP; Ladopoulou, E; Matralis, AN | 1 |
| Tanimoto, T | 1 |
1 review(s) available for succinobucol and Hyperlipemia
| Article | Year |
|---|---|
[Research and developmental strategy of anti-dyslipidemic agents].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Apolipoprotein A-I; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Disease; Disease Models, Animal; Drug Design; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Oligoribonucleotides, Antisense; Probucol; Receptors, G-Protein-Coupled; Receptors, Nicotinic | 2007 |
1 other study(ies) available for succinobucol and Hyperlipemia
| Article | Year |
|---|---|
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats | 2013 |